News

Novo Nordisk to Acquire Emisphere Technologies for $1.8 Billion

November 10, 2020

The agreement provides Novo Nordisk with full access to Emisphere’s Eligen SNAC technology, which will boost Novo Nordisk’s portfolio of oral therapeutics.

FDA Grants Fast Track Designation to Novavax’s COVID-19 Vaccine Candidate

November 10, 2020

The vaccine will enter into a Phase III clinical trial in the United States and Mexico by the end of November, which could potentially support global authorization and approval of the vaccine.

Pfizer: COVID-19 Vaccine Shows High Efficacy

November 09, 2020

Interim efficacy data suggests the Pfizer/BioNTech has an efficacy rate above 90%.

Merck to Acquire VelosBio for $2.75 Billion

November 06, 2020

Through the acquisition, Merck will gain access to VelosBio’s lead investigational candidate, VLS-101, an antibody-drug conjugate that targets receptor tyrosine kinase-like orphan receptor 1.

Janssen Seeks European Approval for Expanded Use of Darzalex SC Formulation

November 06, 2020

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Type II variation application to EMA for expanded use of the SC formulation of Darzalex.

ProteoNic Licenses Protein Expression Technology to Gilead Sciences

November 06, 2020

ProteoNic has licensed its protein expression technology, 2G UNic, to Gilead Sciences.

ACG Invests in Mumbai-Based Start Up IQGEN-X

November 06, 2020

ACG has acquired a significant stake in IQGEN-X, a Mumbai-based start-up contract research organization (CRO).

Lonza Inaugurates New Facility for ADC Payload Manufacturing

November 06, 2020

Lonza has inaugurated its first ADC payload manufacturing suite at the Visp, Switzerland site.

Samsung Biologics Incorporates Solentim’s Cell Line Development Technology into New R&D Center

November 05, 2020

Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.

New EpiMOGRIFY Technology Platform Offers Development Support for Allogeneic Cell Therapies

November 04, 2020

Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.